Abstract
The aim of this study was to establish local resistance profiles of Candida species isolated from various clinical specimens by identifying isolates and determining their susceptibilities to commonly used antifungal agents. All isolates were identified to species level and amphotericin B, flucytosine, fluconazole, voriconazole, caspofungin and micafungin antifungal susceptibility testing was performed using Vitek 2 Compact Advanced Expert System (AES). The specimens consisted of 152 urines (69%), 49 blood (22%), 15 sputum (7%) and 4 wound (2%) samples. Of the 220 isolated Candida strains, the most prevalent species were Candida albicans (43.3%), Candida tropicalis (25%) and Candida parapsilosis (13.7%). In blood specimens C. parapsilosis was the dominant species (43%), followed by C. albicans (32.5%) and C. tropicalis (12.2%). Overall resistance to amphotericin B, flucytosine, fluconazole, voriconazole, caspofungin and micafungin was 7.3%, 10%, 9.4%, 7.3%, 2% and 6.5%, respectively. Due to the increase in patient populations at risk of Candida infections, rational treatment planning and resistance rates should be checked along with antifungal susceptibility testing on C. albicans, C. tropicalis and C. parapsilosis isolates.
Highlights
The aim of this study was to establish local resistance profiles of Candida species isolated from various clinical specimens by identifying isolates and determining their susceptibilities to commonly used antifungal agents
About 90% of invasive infections are caused by Candida albicans, Candida tropicalis, Candida parapsilosis, Candida glabrata and Candida krusei [4]
Investigations in Europe have noted an increase in the prevalence of fungal infections caused by Candida species other-than C. albicans such as C. parapsilosis, C. glabrata and C. krusei, C. albicans still causes about 60% of cases [5,6]
Summary
The aim of this study was to establish local resistance profiles of Candida species isolated from various clinical specimens by identifying isolates and determining their susceptibilities to commonly used antifungal agents. Conclusions: Due to the increase in patient populations at risk of Candida infections, rational treatment planning and resistance rates should be checked along with antifungal susceptibility testing on C. albicans, C. tropicalis and C. parapsilosis isolates. Investigations in Europe have noted an increase in the prevalence of fungal infections caused by Candida species other-than C. albicans such as C. parapsilosis, C. glabrata and C. krusei, C. albicans still causes about 60% of cases [5,6] It seems that marked differences exist in species distributions and resistance to antifungal agents between different countries, emphasizing the need for continued investigation in each country to observe trends in pathogen distribution and drug susceptibilities [7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
